news
Novel inhibitor blocks myeloma cancer cell growth in mouse model
Having identified the histone demethylase KDM5A as a multiple myeloma target, researchers developed a KDM5 inhibitor to treat the cancer.
List view / Grid view
multiple myeloma
article
Preventing stem cells from transforming into pre-leukaemia stem cells
Researchers have discovered that two enzymes called APOBEC3C and ADAR1 work together to fuel the transition from pre-cancer stem cells to cancer stem cells in leukaemia.
news
Novel IRF4 inhibitor shows promise as myeloma treatment in mice
An antisense oligonucleotide has been developed by researchers to inhibit IRF4 as a potential strategy to treat multiple myeloma.
news
New α-radioimmunotherapy shows promise as multiple myeloma treatment in mice
An α-radioimmunotherapy called 212Pb-anti-CD38 was effective at preventing tumour growth and increasing survival in multiple myeloma tumour-bearing mice, a study has shown.
news
New molecule shows efficacy at fighting multiple myeloma in mice
A new compound, called FL118, was effective at combatting multiple myeloma in advanced stages of the condition in patient samples as well as mice, say researchers.
news
CD229 CAR T-cell therapy treated tumours had lasting response mice
Researchers have created a CAR T-cell therapy which targets the CD229 molecule expressed on all multiple myeloma cells and killed human tumour cells in mice.
news
Urine tests are important in diagnosing myeloma
It may be better to examine the urine and the blood of patients suspected of tumours of the plasma cells...
news
Scientists give tumour-fighting cells a boost in battling bone marrow cancer
Researchers uncovered a new way to enhance the function of a specific type of immune cell that destroys tumours in multiple myeloma...
news
Takeda to enrol 5000 patients in giant multiple myeloma trial
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Takeda’s global non-interventional, observational multiple myeloma study is now enrolling patients, aiming to have 5,000 patients over three years with a goal of following each patient for a minimum of five years in an effort to track patterns in disease presentation, patient characteristics, treatment and outcomes, thereby enhancing the understanding…